CFO Jeffrey G. Black bought 22,298 shares of XGN at $2.98; stock near 52-week high of $3.53 as unprofitable biotech seeks growth.
On 2024-11-15, Black Jeffrey G., Chief Financial Officer, purchased 22,298 shares at $2.98, increasing his holdings by 8.8% to 274,492 shares. The transaction occurs near the stock's 52-week high of $3.53 and follows a 22.6% 30-day price rise. Despite revenue growth of 15.3% year-over-year, EXAGEN remains unprofitable, with a net loss of $5,028,000.00 in the latest full fiscal year and a quarterly net loss of $5,028,000.00 against $12,507,000.00 in revenue. The combination of an insider buy from the CFO during a strong price run-up—while the company remains structurally unprofitable—merits careful attention to whether this reflects conviction in a turnaround path or a timed response to recent momentum.